Corcept Therapeutics Inc SEC Filings

Corcept Therapeutics filed a report stating that the U.S. Food and Drug Administration has accepted its New Drug Application for relacorilant as a treatment for patients with platinum-resistant ovarian cancer. This acceptance means the FDA has agreed to review the application for this potential new therapy.

Gillian M. Cannon, a director of Corcept Therapeutics (CORT), executed option activity on 09/04/2025. She exercised 11,000 stock options at an exercise price of $22.99 per share and received 11,000 shares. To cover the exercise cost in a net (cashless) exercise, 3,607 shares were withheld at an implied price of $70.13, leaving 7,393 shares issued to her from that portion. Following these transactions, the filing reports 11,000 common shares directly owned from the exercise and 49,000 derivative securities (stock options) beneficially owned and fully exercisable through their stated expiration date of 12/01/2030.

William Guyer, Chief Development Officer of Corcept Therapeutics (CORT), reported multiple transactions dated 09/02/2025. The filing shows an acquisition of 20,000 common shares and contemporaneous sales of 15,594 and 4,406 common shares at weighted-average prices of $70.392 and $70.8478, respectively, for total shares sold of 20,000. The sales were made pursuant to a 10b5-1 trading plan adopted on 11/27/2024. The report also records a transaction in a derivative security: 20,000 stock options with a $21.65 exercise/conversion price and noted as fully exercisable, and the filing indicates 330,000 derivative securities beneficially owned following the transaction. Following these trades, Mr. Guyer beneficially owns 25,487 common shares directly.

Corcept Therapeutics (CORT) insider Joseph D. Lyon, Chief Accounting & Technology Officer, reported multiple transactions on 09/02/2025 and 09/03/2025. He exercised a stock option with a $13.56 strike for 5,000 shares on 09/02/2025, increasing derivative-based beneficial ownership to 26,571 shares. On the same day he sold a total of 5,000 shares under a 10b5-1 plan (weighted average sale prices noted at $70.2386 and $70.7571), purchased 200 shares under the company Purchase Plan at the closing price ($71.38), received 200 restricted shares at $0 under the Purchase Plan, and had 189 shares withheld to satisfy tax withholding upon vesting. The reporting person adopted the 10b5-1 plan on 08/30/2024. All reported holdings are direct.

Sean Maduck, President of Corcept Endocrinology, reported multiple transactions in Corcept Therapeutics (CORT) on 09/02/2025 and 09/03/2025. He exercised options to acquire 20,000 shares at $5.05 on 09/02/2025 and immediately sold portions under a 10b5-1 plan, selling 15,070 shares at a weighted average price of $70.3787 and 4,930 shares at a weighted average price of $70.8359. He purchased 228 shares under the company Purchase Plan at a closing price and received 228 restricted shares (zero price) that vest in one year. The report discloses indirect holdings via trusts and an LLC and shows tax-withheld shares upon vesting.

Joseph K. Belanoff, Chief Executive Officer and a director of Corcept Therapeutics, reported two open-market sales under a Rule 10b5-1 trading plan on 09/02/2025. The filing discloses a sale of 39,300 shares at a weighted average price of $70.5172 and a separate sale of 700 shares at a weighted average price of $71.0107. After the sales the reported beneficial ownership figures shown in the form are 2,822,070 shares and 2,821,370 shares, held indirectly through the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02, over which the reporting person states he has voting power but disclaims beneficial ownership except for his pecuniary interest. The transactions were made pursuant to a 10b5-1 plan adopted November 26, 2024.

Corcept Therapeutics (CORT) reporting person Atabak Mokari, the company's Chief Financial Officer, executed purchases and experienced withholding tied to restricted stock vesting in early September 2025. On 09/02/2025 the Reporting Person purchased 200 shares under a Purchase Plan at a price established by that day's closing price ($71.38), and was also granted 200 Purchase Plan shares recorded at $0.00. On 09/03/2025 the issuer withheld 144 shares to satisfy tax-withholding obligations related to the vesting of restricted stock units. The filing states the Reporting Person beneficially owned 14,321 shares following these transactions and discloses 231, 232, and 775 shares underlying unvested restricted stock awards that vest 100% on the one-year anniversary of their grant dates if conditions are met.

Corcept Therapeutics (CORT) insider activity: Gary Charles Robb, Chief Business Officer, purchased common stock under the company's 2024 Incentive Award Plan Purchase Plan on September 2, 2025. He acquired 251 shares at a price based on the closing price of $71.38 on that date and separately acquired 251 shares under the Purchase Plan with a reported price of $0 for the restricted-plan component. On September 3, 2025 a transaction coded F shows 256 shares disposed at $71.38 for tax withholding related to vesting. Following these transactions he beneficially owned 13,610 shares directly and 11,571 shares indirectly held in a custodial account for a child. Several restricted stock awards (290, 292, 997 shares) remain unvested and vest one year after grant dates if conditions are met.

Form 144 filed for Corcept Therapeutics, Inc. (CORT) reports a proposed sale of 20,000 common shares to be executed on 09/02/2025 through Stifel Nicolaus & Company, Inc. The shares were acquired the same day by stock option exercise and paid in cash. The filing lists total outstanding shares of 105,370,000 and an aggregate market value for the proposed sale of $1,394,400.00. The notice also discloses multiple sales by the same holder, William Guyer, during the prior three months, including a sale of 35,007 shares on 08/08/2025 for $2,512,452.00. The filer certifies there is no undisclosed material adverse information.